Outlook Management expects to initiate Phase 3 trials for subcutaneous VK2735 in Q2 2025, focusing on obesity and type 2 diabetes populations. The trials will incorporate a 52-week treatment ...

TROPION-Lung15 is a global, multicenter, open-label, three-arm phase 3 trial where patients will be randomized in a 1:1:1 ratio to evaluate the efficacy and safety of datopotamab deruxtecan (6.0 ...